Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.
- Conditions
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 36
- Registration Number
- NCT05594602
- Locations
- 🇺🇸
ICON, plc., Lenexa, Kansas, United States
Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- Combined Military Hospital Abbottabad
- Target Recruit Count
- 100
- Registration Number
- NCT05578950
- Locations
- 🇵🇰
Cmh Abbottabad, Abbottābād, Khyber Pakhtunkhwa, Pakistan
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05573724
- Locations
- 🇷🇴
Research Site, Cluj-Napoca, Romania
Comparative Study Between Pulsed and Continuous Itraconazole for the Treatment of Onychomycosis
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Combined Military Hospital Abbottabad
- Target Recruit Count
- 60
- Registration Number
- NCT05567484
- Locations
- 🇵🇰
cmh Abbottabad, Abbottabad, Khyber Pakhtunkhwa, Pakistan
A Study to Evaluate the Drug-drug Interaction Effect of Itraconazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05568082
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 78
- Registration Number
- NCT05563766
- Locations
- 🇺🇸
VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto, California, United States
🇺🇸VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States
🇺🇸Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT05551897
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05538312
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 64
- Registration Number
- NCT05518734
- Locations
- 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Cardurion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05437094
- Locations
- 🇺🇸
Cardurion Investigative Site, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.